# FDA

Type: organization

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/fda-organization
Canonical HTML page: https://gethealthbrief.com/entity/fda-organization

## Timeline

- **2026-10-30**: PDUFA Date — Target date for FDA decision on INO-3107 accelerated approval.
- **2026-Q4**: APOLLO Data Readout — Expected release of Phase 2 data which will support the traditional NDA filing.
- **2026-Q4**: Expected Finalization — Anticipated period for final guidance after public comment and review.
- **2026-07-16**: NPR Analysis Reveals Limited Coverage — Analysis finds only 92 drug deals, covering fewer than 12% of participating companies' brand-name portfolios.
- **2026-07-16**: FDA approves Merck's Lipfendra — The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
- **2026-06-30**: Type B FDA Meeting Target — Planned follow-up to define Phase III and regulatory path for AMT-130.
- **2026-06-30**: AMT-260 Data Readout — Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
- **2026-06-30**: Platform Modernization — LivePerson expects to complete its multiyear platform modernization.
- **2026-06-23**: STAT News publishes exposé — Citing three anonymous sources, STAT reports the compassionate use approval and notes that top health officials took an unusual interest, prompting speculation the patient was 'well connected.' The outlet asked the White House about Trump's possible involvement due to demographic overlap.
- **2026-06-23**: White House denial — Same day, White House spokesman Kush Desai denies on X that the application was for President Trump, with other officials calling the reporting false. They do not confirm the patient's identity.
- **2026-05**: Marty Makary resigns as FDA Commissioner — Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
- **2026-04-01**: Price Adjustments — Anticipated first wave of price increases for non-contracted generic drugs in the U.S. and EU markets.
- **2026-04**: Compassionate use request submitted — A senior NIH clinician seeks FDA and Eli Lilly permission for a 79-year-old man to receive retatrutide to treat refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
- **2026-03-24**: Current Data Release — National reports show abortion numbers holding steady despite 14+ state bans.
- **2026-03-24**: FDA Warning Issued — The FDA flags the podcast statements as misleading and issues an Untitled Letter to ImmunityBio.

## Recent coverage (20 stories)

### Cyclospora Cases Surge 560% to 1,645: Taylor Farms Recalls Lettuce in 27 States
2026-07-19 02:43:18 · Sentiment: Bearish · Impact: 6/10 · Sources: 2

A record cyclospora outbreak with 1,645 confirmed cases and 141 hospitalizations prompts Taylor Farms to recall shredded lettuce linked to the parasite. Healthcare providers face a surge in diagnosis and treatment demands as thousands of additional illnesses are investigated.
Full story: https://gethealthbrief.com/story/cyclospora-outbreak-1645-cases-27-states-recall

### Merck's Lipfendra: 59% LDL Cut with First Oral PCSK9 Pill Approved
2026-07-16 23:20:10 · Sentiment: Bullish · Impact: 8/10 · Sources: 7

The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Full story: https://gethealthbrief.com/story/merck-lipfendra-oral-pcsk9-pill-59-percent-ldl-cut-health-systems

### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions
2026-07-16 22:00:46 · Sentiment: Very Bullish · Impact: 9/10 · Sources: 132

The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access

### TrumpRx: 92 Drug Deals Cover <12% of Brand-Name Portfolio
2026-07-16 13:45:20 · Sentiment: Neutral · Impact: 6/10 · Sources: 12

Six months after launch, the government’s TrumpRx drug discount portal offers just 92 brand-name medications—less than 12% of products from participating pharma firms—leaving gaps in cancer, HIV, and inflammatory disease treatments. Health policy experts question its scalability as a long-term cost-containment tool.
Full story: https://gethealthbrief.com/story/trumprx-92-deals-cover-less-than-12-percent

### UniQure Surges 78% as FDA Greenlights BLA for Huntington's Gene Therapy AMT-130
2026-07-12 05:40:15 · Sentiment: Very Bullish · Impact: 8/10 · Sources: 2

The FDA’s decision to accept existing AMT-130 clinical data for a BLA submission could fast-track the first disease-modifying treatment for Huntington’s disease, with major implications for healthcare systems, payers, and patients.
Full story: https://gethealthbrief.com/story/uniqure-surges-78-fda-huntingtons-gene-therapy-health

### FDA Expands Gene Therapy to Kids 2+, Offering $2.2M Cure for Sickle Cell
2026-07-09 07:50:49 · Sentiment: Bullish · Impact: 8/10 · Sources: 20

The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
Full story: https://gethealthbrief.com/story/fda-approves-casgevy-pediatric-sickle-cell-health

### White House Denies 79-Year-Old Trump Received Early Access to Lilly's Retatrutide Under Compassionate Use
2026-06-25 12:26:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The White House denied that President Trump is the 79-year-old patient granted compassionate use of Lilly’s investigational weight-loss drug retatrutide, intensifying scrutiny over equity and transparency in the FDA’s expanded access program for experimental obesity treatments.
Full story: https://gethealthbrief.com/story/white-house-denies-trump-early-access-retatrutide

### FDA Recall: 3 Infants Hospitalized with Botulism After Organic Formula
2026-06-15 09:51:35 · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2

Three infants in three states were diagnosed with botulism after consuming Nara Organics powdered formula, prompting a voluntary recall of all whole milk formula. All babies recovered, but the FDA and CDC investigation highlights risks of powdered formula for newborns and emphasizes clinical vigilance among pediatricians.
Full story: https://gethealthbrief.com/story/nara-organic-formula-recall-3-infants-botulism-health

### FDA approves first new sunscreen filter in 30 years — what it means for skin cancer prevention
2026-06-14 10:17:29 · Sentiment: Bullish · Impact: 7/10 · Sources: 18

The FDA has approved bemotrizinol, a broad-spectrum UV filter used in Europe and Asia, marking the first new chemical sunscreen ingredient in the U.S. in nearly three decades. Dermatologists praise its photostability and dual protection, which could improve skin cancer prevention and reduce irritation associated with avobenzone.
Full story: https://gethealthbrief.com/story/fda-approves-bemotrizinol-sunscreen

### PTFE Membrane and CDMO Markets Surge Amid Sterile Manufacturing Demand
2026-03-26 07:25:33 · Sentiment: Neutral · Impact: 6/10 · Sources: 4

The convergence of advanced PTFE membrane technology and the expanding pharmaceutical CDMO sector is driving a new era of sterile manufacturing. As drug complexity rises, the demand for high-performance filtration and outsourced production capacity is reaching record levels.
Full story: https://gethealthbrief.com/story/ptfe-membrane-cdmo-market-growth-2026

### The AI Doc: Oscar-Winning Filmmakers Tackle Healthcare’s AI Paradox
2026-03-24 21:20:52 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

A new documentary titled 'The AI Doc,' produced by Oscar-winning filmmakers, explores the dual nature of artificial intelligence as both a transformative force and a systemic risk. For the healthcare industry, the film highlights the critical tension between clinical efficiency and the ethical dangers of algorithmic bias.
Full story: https://gethealthbrief.com/story/the-ai-doc-documentary-healthcare-implications

### FDA Issues Warning to ImmunityBio Over Soon-Shiong’s Cancer Drug Claims
2026-03-24 20:18:40 · Sentiment: Bearish · Impact: 7/10 · Sources: 2

The FDA has issued a formal warning to ImmunityBio and its founder, Patrick Soon-Shiong, regarding misleading public statements about the company's bladder cancer drug. The regulator cited claims made during a podcast that suggested broader efficacy than currently approved, raising concerns about off-label promotion.
Full story: https://gethealthbrief.com/story/fda-warning-immunitybio-soon-shiong-misleading-claims

### Compass Pathways Reports 2025 Results as Pivotal Phase 3 Data Looms
2026-03-24 15:41:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
Full story: https://gethealthbrief.com/story/compass-pathways-2025-financial-results-comp360

### Medication Abortion Becomes Primary Method Amid Escalating Regulatory Warfare
2026-03-24 07:42:54 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
Full story: https://gethealthbrief.com/story/medication-abortion-regulation-trends-2026

### U.S. Abortion Rates Remain Resilient Amid State Bans: The Role of Health IT
2026-03-24 07:42:14 · Sentiment: Neutral · Impact: 7/10 · Sources: 10

New data reveals that the total number of abortions in the United States has remained stable despite a wave of state-level bans and restrictions. This trend is largely driven by the rapid expansion of telehealth services and medication abortion, highlighting a significant shift in how reproductive healthcare is delivered and regulated.
Full story: https://gethealthbrief.com/story/us-abortion-rates-telehealth-resilience-2026

### FDA Issues Urgent Recall for Alcohol Prep Pads Over Bacterial Risks
2026-03-23 18:44:01 · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2

A widespread recall has been initiated for alcohol prep pads following reports of life-threatening bacterial contamination. The recall affects products used across hospitals, clinics, and home care settings, raising significant concerns regarding sepsis risks for immunocompromised patients.
Full story: https://gethealthbrief.com/story/alcohol-pad-recall-bacterial-contamination-2026

### Scaling Diabetes Care: The 2026 Outlook for Glucometer Manufacturing
2026-03-23 09:02:25 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As global diabetes prevalence reaches record highs, the shift toward localized medical device production is driving a surge in glucometer manufacturing plant investments for 2026. This briefing analyzes the cost structures, regulatory hurdles, and technological requirements for establishing high-volume diagnostic production facilities.
Full story: https://gethealthbrief.com/story/glucometer-manufacturing-plant-setup-2026-cost-analysis

### White House Unveils Comprehensive AI Regulatory Framework for Healthcare
2026-03-22 16:26:02 · Sentiment: Neutral · Impact: 8/10 · Sources: 3

The White House has released a definitive regulatory framework for artificial intelligence, establishing mandatory safety and transparency standards for high-stakes sectors. For healthcare, the move shifts the industry from voluntary guidelines to a rigorous clinical validation and algorithmic accountability regime.
Full story: https://gethealthbrief.com/story/white-house-ai-regulation-framework-healthcare-2026

### Rare Lab: Inside the AI-Powered Frontier of Orphan Drug Discovery
2026-03-22 15:19:39 · Sentiment: Bullish · Impact: 6/10 · Sources: 3

Rare Lab is pioneering a high-throughput, AI-driven approach to identify therapeutic candidates for neglected rare diseases. By integrating generative AI with automated laboratory testing, the firm aims to drastically reduce the time and cost of drug development for the world's rarest conditions.
Full story: https://gethealthbrief.com/story/rare-lab-ai-drug-discovery-orphan-diseases

### The Eroding Aura: How Generative AI is Redefining the Physician's Authority
2026-03-22 00:26:38 · Sentiment: Neutral · Impact: 6/10 · Sources: 3

The integration of large language models like ChatGPT and Claude into clinical settings is fundamentally altering the traditional physician-patient relationship. Bioethicist Dr. John Lantos warns that the transition from 'invisible' diagnostic AI to 'visible' interactive AI is eroding the historical authority of doctors in a regulatory vacuum.
Full story: https://gethealthbrief.com/story/ai-physician-aura-transformation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.